Navigation Links
American Medical Systems and Allergan Sign Agreement for JetTouch™/BOTOX® Co-Development Program
Date:6/7/2012

CHADDS FORD, Pa., June 7, 2012 /PRNewswire-FirstCall/ -- American Medical Systems (AMS), an Endo Health Solutions company (Nasdaq: ENDP), announced today it has signed a co-development agreement with Allergan, Inc. to jointly develop and seek regulatory approval for the delivery of BOTOX®  (onabotulinumtoxinA)  using the JetTouch™ system for treatment of overactive bladder (OAB).

AMS' JetTouch™ is a novel injection platform that has the potential to enable needle-free injection into any area of the body reachable by endoscopic or percutaneous access. Needle-free injection with the JetTouch™ system is being evaluated as an innovative means for local drug delivery and may provide treatment administration efficiencies for the physician. 

BOTOX® was approved by the U.S. Food and Drug Administration (FDA) in August 2011 for the treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition (e.g. spinal cord injury, multiple sclerosis) in adults who have an inadequate response to or are intolerant of an anticholinergic medication. BOTOX® is currently under FDA review as a potential treatment for OAB with symptoms of urinary incontinence, urgency and frequency in adult patients who have an inadequate response to or are intolerant of an anticholinergic medication.

"Endo Health Solutions continues to focus on expanding its therapeutic offerings in urology and exploring innovative options for patients," said Dr. Ivan Gergel, Executive Vice President of R&D and Chief Scientific Officer of Endo Health Solutions. "With AMS' position in the urology marketplace, the potential of the JetTouch™ system combined with the delivery of BOTOX® make this a mutually beneficial business opportunity."

Under the co-development agreement, AMS will first develop JetTouch™ for general use in the bladder. Subject to the FDA approval of BOTOX® for injection by needle as a treatment for OAB, AMS, in collaboration with Allergan, will seek to add BOTOX® to the JetTouch™ label, and Allergan plans to seek regulatory advice to add the delivery of BOTOX® with JetTouch™ to the BOTOX® label. 

About American Medical Systems
American Medical Systems, headquartered in Minnetonka, Minnesota, is a diversified supplier of medical devices and procedures to treat incontinence, erectile dysfunction, benign prostatic hyperplasia (BPH), pelvic floor prolapse and other pelvic disorders in men and women. These disorders can significantly diminish one's quality of life and profoundly affect social relationships. In recent years, the number of people seeking treatment has increased markedly as a result of longer lives, higher-quality-of-life expectations and greater awareness of new treatment alternatives. American Medical Systems' products reduce or eliminate the incapacitating effects of these diseases, often through minimally invasive therapies. The Company's products were used to treat approximately 340,000 patients in 2010. AMS is part of Endo Health Solutions Inc. (Nasdaq: ENDP), a diversified healthcare company that is dedicated to improving care through a combination of branded products, generics, devices, technology and services. (http://www.endo.com).

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements.  Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in our Annual Report on Form 10-K. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

BOTOX is a registered trademark of Allergan, Inc.


'/>"/>
SOURCE Endo Health Solutions Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. American Oriental Bioengineering Inc. Announces Suspension of Trading in its Common Stock and the Initiation of Delisting Proceedings by NYSE
2. Attack on the Website of the American Pharmacists Association
3. American Society of Hematology Statement on House Passage of Prescription Drug User Fee Act (PDUFA)
4. COPD Tops Asthma as the Focus Indication for Next Generation Respiratory Therapies at the 2012 American Thoracic Society Conference
5. Novocure™ to Present NovoTTF™ Therapy Data at the 2012 Annual Scientific Meeting of the American Society of Clinical Oncology
6. EQUICARE CS Cancer Survivorship Case Management Software Listed as a "Best Practices" Resource by the American College of Surgeons Commission on Cancer (COC)
7. Agendia Announces Nine Studies in Breast and Colon Cancer for Presentation at 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO)
8. American Society of Hematology Statement on Senate Passage of Prescription Drug User Fee Act (PDUFA)
9. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
10. Percutaneous Tibial Nerve Stimulation Included in the American Urological Associations Overactive Bladder Clinical Treatment Guidelines
11. Purdue Pharma L.P. To Present Analysis Of Butrans® (buprenorphine) Transdermal System CIII Clinical Data At American Pain Society Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... VENICE, Fla. , Feb. 5, 2016 /PRNewswire/ ... Centers , is the first of its kind ... of undesired tattoos through advanced laser treatment. The ... Florida,s Suncoast by storm with ... video consultations, and advanced multi-wavelength Astanza Trinity technology. ...
(Date:2/5/2016)... 2016  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... underwritten secondary offering of 11,027,558 shares of its common ... of Blackstone and Goldman Sachs.  The shares are being ... $96.45 per share. The selling stockholders will receive all ... nor any of its directors, officers or other stockholders ...
(Date:2/5/2016)... Site Profile: --> ... The Speech Recognition People, announced their latest primary healthcare case study ... reduce turnaround times and to save the practice money. ... 2013 Challenge: --> ,- Wirral CCG ,- ... Six doctors ,- Wirral CCG ,- VoicePower client since 2013 ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure ... to search for and donate to Give To Cure’s campaign that is crowdfunding clinical ... lets users make and share payments through a smart device. In 2015 alone, Venmo ...
(Date:2/5/2016)... New York (PRWEB) , ... February 05, 2016 , ... ... the election of Patrick McDermott as Chairman of the National Board of Directors. Mr. ... as Chairman of the Board,” stated Leslie A. Chambers , APDA President and ...
(Date:2/5/2016)... San Francisco, CA (PRWEB) , ... February 05, ... ... dentist and founder of CitiDent, announces that it is now welcoming ... by Dr. Cheng, CitiDent offers a complete range of oral health care, including ...
(Date:2/5/2016)... ... 2016 , ... Health and wellness is a topic that should concern all ... are experiencing an illness. Migraines are a severe form of a headache and often ... not wish the pain on their worst enemy, the feeling can last for many ...
(Date:2/5/2016)... ... , ... Calls Blacklist has just been updated by mobile app developer Vlad ... has fixed known bugs within the app. Calls Blacklist allows its users to only ... any of their device’s battery power or memory. It provides a powerful call blocker ...
Breaking Medicine News(10 mins):